Miguel García-Ortegón

Miguel García-Ortegón

Auto-generated profile, based on publicly available information

Miguel García-Ortegón

University of Cambridge

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Chemical Research in Toxicology
Verified
Journal Article
Open access
SSSrijit Seal
Srijit Seal
MMManas Mahale
Manas Mahale
MGMiguel García-Ortegón
Miguel García-Ortegón
CJChaitanya K. Joshi
Chaitanya K. Joshi
LHLayla Hosseini-Gerami
Layla Hosseini-Gerami
ABAndreas Bender
Andreas Bender
Machine learning (ML) is increasingly valuable for predicting molecular properties and toxicity in drug discovery. However, toxicity-related end points have always been challenging to evaluate experimentally with respect to in vivo translation due to the required resources for human and animal studies; this has impacted data availability in the field. ML can augment or even potentially replace traditional experimental processes depending on the project phase and specific goals of the prediction. For instance, models can be used to select promising compounds for on-target effects or to deselect those with undesirable characteristics (e.g., off-target or ineffective due to unfavorable pharmacokinetics). However, reliance on ML is not without risks, due to biases stemming from nonrepresentative training data, incompatible choice of algorithm to represent the underlying data, or poor model building and validation approaches. This might lead to inaccurate predictions, misinterpretation of the confidence in ML predictions, and ultimately suboptimal decision-making. Hence, understanding the predictive validity of ML models is of utmost importance to enable faster drug development timelines while improving the quality of decisions. This perspective emphasizes the need to enhance the understanding and application of machine learning models in drug discovery, focusing on well-defined data sets for toxicity prediction based on small molecule structures. We focus on five crucial pillars for success with ML-driven molecular property and toxicity prediction: (1) data set selection, (2) structural representations, (3) model algorithm, (4) model validation, and (5) translation of predictions to decision-making. Understanding these key pillars will foster collaboration and coordination between ML researchers and toxicologists, which will help to advance drug discovery and development.

18 July 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
MGMiguel García-Ortegón
Miguel García-Ortegón
GSGregor N. C. Simm
Gregor N. C. Simm
ATAustin J. Tripp
Austin J. Tripp
JLJose Miguel Hernandez Lobato
Jose Miguel Hernandez Lobato
ABAndreas Bender
Andreas Bender
SBSergio Bacallado
Sergio Bacallado
The field of machine learning for drug discovery is witnessing an explosion of novel methods. These methods are often benchmarked on simple physicochemical properties such as solubility or general druglikeness, which can be readily computed. However, these properties are poor representatives of objective functions in drug design, mainly because they do not depend on the candidate compound's interaction with the target. By contrast, molecular docking is a widely applied method in drug discovery to estimate binding affinities. However, docking studies require a significant amount of domain knowledge to set up correctly, which hampers adoption. Here, we present dockstring, a bundle for meaningful and robust comparison of ML models using docking scores. dockstring consists of three components: (1) an open-source Python package for straightforward computation of docking scores, (2) an extensive dataset of docking scores and poses of more than 260,000 molecules for 58 medically relevant targets, and (3) a set of pharmaceutically relevant benchmark tasks such as virtual screening or de novo design of selective kinase inhibitors. The Python package implements a robust ligand and target preparation protocol that allows nonexperts to obtain meaningful docking scores. Our dataset is the first to include docking poses, as well as the first of its size that is a full matrix, thus facilitating experiments in multiobjective optimization and transfer learning. Overall, our results indicate that docking scores are a more realistic evaluation objective than simple physicochemical properties, yielding benchmark tasks that are more challenging and more closely related to real problems in drug discovery.

1 February 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
SSSrijit Seal
Srijit Seal
OSOla Spjuth
Ola Spjuth
LHLayla Hosseini-Gerami
Layla Hosseini-Gerami
MGMiguel García-Ortegón
Miguel García-Ortegón
SSShantanu Singh
Shantanu Singh
ACAnne E. Carpenter
Anne E. Carpenter
Drug-induced cardiotoxicity (DICT) is a major concern in drug development, accounting for 10-14% of postmarket withdrawals. In this study, we explored the capabilities of chemical and biological data to predict cardiotoxicity, using the recently released DICTrank data set from the United States FDA. We found that such data, including protein targets, especially those related to ion channels (e.g., hERG), physicochemical properties (e.g., electrotopological state), and peak concentration in plasma offer strong predictive ability for DICT. Compounds annotated with mechanisms of action such as cyclooxygenase inhibition could distinguish between most-concern and no-concern DICT. Cell Painting features for ER stress discerned most-concern cardiotoxic from nontoxic compounds. Models based on physicochemical properties provided substantial predictive accuracy (AUCPR = 0.93). With the availability of omics data in the future, using biological data promises enhanced predictability and deeper mechanistic insights, paving the way for safer drug development. All models from this study are available at https://broad.io/DICTrank_Predictor.

16 September 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
MGMiguel García-Ortegón
Miguel García-Ortegón
SSSrijit Seal
Srijit Seal
EGEmily Geddes
Emily Geddes
JLJenny L. Littler
Jenny L. Littler
CGCollette S. Guy
Collette S. Guy
SBSergio Bacallado
Sergio Bacallado
We introduce a transfer learning framework using deep graph neural networks (DGNNs) to identify antibacterials from ultra-large chemical libraries.

18 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSrijit Seal
Srijit Seal
OSOla Spjuth
Ola Spjuth
LHLayla Hosseini-Gerami
Layla Hosseini-Gerami
MGMiguel García-Ortegón
Miguel García-Ortegón
SSShantanu Singh
Shantanu Singh
ACAnne E. Carpenter
Anne E. Carpenter
Drug-induced cardiotoxicity (DICT) is a major concern in drug development, accounting for 10-14% of postmarket withdrawals. In this study, we explored the capabilities of various chemical and biological data to predict cardiotoxicity, using the recently released Drug-Induced Cardiotoxicity Rank (DICTrank) dataset from the United States FDA. We analyzed a diverse set of data sources, including physicochemical properties, annotated mechanisms of action (MOA), Cell Painting, Gene Expression, and more, to identify indications of cardiotoxicity. We found that such data, including protein targets, especially those related to ion channels (such as hERG), physicochemical properties (such as electrotopological state) as well as peak concentration in plasma offer strong predictive ability as well as valuable insights into DICT. We also found compounds annotated with particular mechanisms of action, such as cyclooxygenase inhibition, could distinguish between most-concern and no-concern DICT compounds. Cell Painting features related to ER stress discern the most-concern cardiotoxic compounds from non-toxic compounds. While models based on physicochemical properties currently provide substantial predictive accuracy (AUCPR = 0.93), this study also underscores the potential benefits of incorporating more comprehensive biological data in future DICT predictive models. With the availability of - omics data in the future, using biological data promises enhanced predictability and delivers deeper mechanistic insights, paving the way for safer therapeutic drug development. All models and data used in this study are publicly released at https://broad.io/DICTrank_Predictor

10 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMiguel Garcia-Ortegon
Miguel Garcia-Ortegon
SSSrijit Seal
Srijit Seal
SSShantanu Singh
Shantanu Singh
ABAndreas Bender
Andreas Bender
SBSergio Bacallado
Sergio Bacallado
Adverse drug reactions (ADRs) are a major source of concern in the development of novel pharmaceuticals. ADRs may be identified in the late stages of development or even after commercialization, which may lead to failure or discontinuation after spending enormous resources on candidate molecules. Thus, predicting ADRs early in the process could help reduce costs by avoiding future failures. However, due to the low number of drugs approved, the amount of historical datapoints on ADRs is limited, which makes their prediction challenging for traditional chemoinformatics methods. Interestingly, each approved drug may have been annotated for hundreds of ADRs, which opens the door to framing ADR prediction as a multi-task or meta-learning problem. In this work, we adopt a meta-learning approach to ADR prediction by applying conditional neural processes (CNPs) to the publicly available Side Effect Resource (SIDER). Our results suggest that CNPs are competitive against single-task baselines even when trained on sparse datasets with missing labels. Furthermore, we find that their predictions are well-calibrated. Finally, we evaluate their performance on ADRs associated to different physiological systems and confirm good predictions across organ classes. Our findings suggest that meta-learning strategies may be beneficial for data-limited clinical endpoints like ADRs.